Articles related to CANCER CARE

The recent proposal by CMS to cut radiation therapy reimbursement by 2% in 2024 has led to serious concerns among radiation oncology specialists. With cumulative reductions reaching 20% over the past decade, the potential impact on patient access, especially in rural areas, and the perceived devaluation of the field are urgent issues that call for thoughtful consideration and response.

The recent study exploring the Mark Cuban Cost Plus Drug Company’s potential impact on Medicare’s oncology drug spending uncovers significant savings opportunities. Physicians may find interest in this model’s potential to improve access to essential cancer medications through reduced costs, emphasizing a call to examine current overpayment within the Medicare system.

The Evolution of Radiation Therapy Explore the evolution of radiation therapy with Dr. Heath Skinner and understand the advancements in 3DCRT, IMRT/VMAT, proton therapy, stereotactic radiation, and brachytherapy. Dr. Heath D. Skinner, esteemed chair and medical director of the Department of Radiation Oncology at UPMC Hillman Cancer Center, delves into the dynamic and transformative world of radiation oncology in this enlightening Continuing Medical Education (CME) activity. A noted specialist in the treatment of head, neck, and lung cancer, Dr. Skinner’s commitment to advancing clinical research underscores his discussions, which aim to educate and inform on the significant advancements in radiation therapy over recent decades. The CME activity is designed as a comprehensive examination of the evolution of radiation therapy. Dr. Skinner outlines a clear trajectory of progress, highlighting the development from conventional three-dimensional conformal radiation therapy (3DCRT) to more sophisticated techniques such as intensity-modulated radiation therapy/volumetric-modulated arc therapy (IMRT/VMAT), and further to the precision of proton therapy. These techniques, each with unique advantages, have shaped modern oncology practices and offer promising improvements in patient outcomes. Further delving into the field, Dr. Skinner also elucidates the intricacies of stereotactic radiation and brachytherapy as additional pillars in the modern cancer treatment paradigm. […]

After completing this CE activity, optometrists who work with cancer patients should be better able to recognize the potential ocular side effects of targeted cancer therapies, monitor patients on these drugs for potential ocular adverse events, consult with specialists as needed, and educate their patients about how these medications may affect their eye health.